US-based Gilead Sciences has formed a strategic alliance with Tango Therapeutics for the discovery, development and commercialisation of new targeted immuno-oncology therapies.
Tango Therapeutics will be responsible for target discovery and validation under the multi-year partnership. Gilead will hold the option to claim global rights for up to five targets resulting from Tango’s functional genomics-based discovery platform.
As per the terms of the agreement, Tango will retain the option to co-develop and co-detail two programmes, involving these targets, in the US.
Gilead Sciences chief scientific officer and R&D head John McHutchison said: “Tango has built a unique discovery platform that we hope will help create the next generation of cancer therapies.
“Our collaboration will combine Tango’s innovative discovery technology alongside Gilead’s drug discovery and development capabilities to build a pipeline of novel immuno-oncology therapies.”
Gilead will pay $50m upfront to Tango Therapeutics, which is also eligible for about $1.7bn in additional pre-clinical fees and development, regulatory and commercial milestones across all programmes.
Additionally, Tango will receive double-digit tiered royalties on net sales, and will equally share profits and losses with Gilead on programmes that it decides to co-develop and co-detail in the US.
Development costs will be proportionate to product rights, and Tango will be eligible to further obtain milestone payments and royalties on ex-US sales.
Tango Therapeutics president and CEO Barbara Weber said: “Gilead is the ideal partner to help us bring potentially transformative treatments to patients with cancer. This partnership has significant strategic value for us.
“With Gilead as our partner, we can maximise the applications of our platform in immuno-oncology, while continuing to independently advance our lead programmes into the clinic and beyond.”